Secondary analysis of a phase 3 ulcerative colitis trial (387 patients): an AI endoscopic cumulative disease score agreed better than the Mayo endoscopic score with symptomatic remission (kappa 0.72 vs 0.57) and quality of life.
Secondary analysisn = 387
Stidham et al. Artificial Intelligence Analysis of Endoscopy Outperforms Conventional Endoscopic Scoring for Agreement With Symptoms and Quality of Life in a Phase 3 Ulcerative Colitis Trial